利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.194 秒)

    Inhibition of hepatitis B virus (HBV) replication by RNA interference
    6.
    发明授权
    Inhibition of hepatitis B virus (HBV) replication by RNA interference 有权
    通过RNA干扰抑制乙型肝炎病毒（HBV）复制

    公开(公告)号：US07067249B2

    公开(公告)日：2006-06-27

    申请号：US10848736

    申请日：2004-05-19

    申请人： Hsiang-Fu Kung ,  Ming-Liang He

    发明人： Hsiang-Fu Kung ,  Ming-Liang He

    IPC分类号： C07H21/04

    CPC分类号： C12N15/1131 ,  A61K48/00 ,  C07H21/04 ,  C07K14/005 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2730/10122

    摘要： The present invention relates to the inhibition of Hepatitis B virus (HBV) replication by RNA molecules of the present invention. Specifically, the RNA molecules of the present invention are double-stranded ribonucleic acid molecules (dsRNA). Specifically, the invention relates to small interfering RNAs (siRNA) which are double-stranded RNAs that direct the sequence-specific degradation of messenger RNA in mammalian cells. The invention relates to development of a new anti-HBV therapy by inhibition of Hepatitis B Virus (HBV) replication using stably-expressed short hairpin RNAs (shRNA), which degrade HBV pregenomic RNA and message RNAs. Included are methods of treatment of cancer by the administration of RNA molecules of the present invention in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, biological therapies/immunotherapies and/or radiation therapies.

    摘要翻译： 本发明涉及通过本发明的RNA分子对乙型肝炎病毒（HBV）复制的抑制。 具体地说，本发明的RNA分子是双链核糖核酸分子（dsRNA）。 具体地，本发明涉及作为引导哺乳动物细胞中信使RNA的序列特异性降解的双链RNA的小干扰RNA（siRNA）。 本发明涉及通过使用稳定表达的短发夹RNA（shRNA）抑制乙型肝炎病毒（HBV）复制来降低HBV前基因组RNA和消息RNA来开发新的抗HBV治疗。 包括通过单独或与标准和实验化学疗法，激素治疗，生物疗法/免疫疗法和/或放射疗法单独或进一步组合的本发明的RNA分子的给药方法来治疗癌症的方法。

    Animal model for fetal alcohol syndrome and methods of treatment
    7.
    发明申请
    Animal model for fetal alcohol syndrome and methods of treatment 审中-公开
    胎儿酒精综合征动物模型及治疗方法

    公开(公告)号：US20060037085A1

    公开(公告)日：2006-02-16

    申请号：US11192194

    申请日：2005-07-28

    申请人： Ying Peng ,  Marie Lin ,  Hsiang-Fu Kung ,  Pai-Hao Yang

    发明人： Ying Peng ,  Marie Lin ,  Hsiang-Fu Kung ,  Pai-Hao Yang

    IPC分类号： A01K67/027

    CPC分类号： A61K49/0008 ,  A01K2227/50 ,  A01K2267/03 ,  G01N33/5088 ,  G01N2800/368

    摘要： A Xenopus laevis (the African clawed frog) embryo model is provided to study the effects of alcohol on fetal development. Exposure of Xenopus embryos in specific developmental stages to alcohol results in tadpoles with microencephaly and growth retardation, in a dose- and time-dependent manner, similar to those observed in human fetal alcohol syndrome (FAS). The invention further provides methods for screening an agent to determine its usefulness for preventing or treating FAS. Moreover, the invention provides methods for preventing or treating FAS in an animal by administering an agent, such an agent includes vitamin C and a catalase, which causes or enhances an expression of Pax6 that is a neural and eye marker. In addition, the invention provides methods for preventing or treating FAS by administering an agent, such as vitamin C, which causes suppression of NF-κB activation.

    摘要翻译： 提供非洲爪蟾（非洲爪青蛙）胚胎模型来研究酒精对胎儿发育的影响。 在特定发育阶段将非洲爪蟾胚胎暴露于酒精会导致与罹患微小aly aly和生长迟缓的ad，以剂量和时间依赖的方式，与人胎儿酒精综合征（FAS）中观察到的相似。 本发明还提供筛选试剂以确定其用于预防或治疗FAS的用途的方法。 此外，本发明提供了通过施用药剂来预防或治疗动物FAS的方法，所述药剂包括维生素C和过氧化氢酶，其引起或增强作为神经和眼睛标记物的Pax6的表达。 此外，本发明提供了通过施用抑制NF-κB活化的诸如维生素C的试剂来预防或治疗FAS的方法。